News
-
-
-
COMMUNIQUÉ DE PRESSE
Adnexus Biotechnologies Partners with 1606 Corp. for Strategic Investment to Revolutionize AI-Driven Drug Discovery
1606 Corp. announces signing a Letter of Intent to acquire a stake in Adnexus Biotechnologies Inc., focusing on AI-driven drug discovery for infectious and neurological diseases -
-
-
COMMUNIQUÉ DE PRESSE
1606 Corp. Signs Letter of Intent to Acquire a Strategic Stake in Adnexus, a Leading AI Biotech Company
1606 Corp. (OTC Pink: CBDW) signs LOI to acquire stake in Adnexus, enhancing AI capabilities in healthcare & biotech. Partnership aims to drive innovation & value for shareholders -
-
-
COMMUNIQUÉ DE PRESSE
1606 Corp. Highlights New Leadership, AI Chatbots Innovations, and Quarterly Reporting Update After Q2 Filling
1606 Corp. announces significant updates for Q2 2024, led by new CEO Austen Lambrecht. Advancements in AI tech, global expansion, and Form 10-Q filing. Focus on AI marketing growth and strategic vision -
